Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Paynter

Orthopaedic Surgery Anchorage, AK Medical Doctor

NPI 1831234798 CMS profile 355259

3801 Lake Otis Pkwy Ste 300, Anchorage, AK 99508

Open in the dashboard

General payments

$13,892

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Paynter of Anchorage, AK is reported in the CMS Open Payments database as having received $13,892 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,292 30
2024 General $1,518 24
2023 General $1,418 26
2022 General $2,481 21
2021 General $230 6
2020 General $2,039 8
2019 General $1,915 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Paynter
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Paynter were reported at $4,292. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Paynter Orthopaedic Surgery median Middle half National median
2019 $1,915 $644 $140–$2,844 $163
2020 $2,039 $312 $75–$1,860 $114
2021 $230 $520 $117–$2,495 $132
2022 $2,481 $598 $128–$2,731 $149
2023 $1,418 $461 $128–$2,264 $160
2024 $1,518 $497 $134–$2,475 $164
2025 $4,292 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,122 83 payments
  2. Arthrex, Inc. $4,489 30 payments
  3. Summit Surgical Corp. $1,270 2 payments
  4. Wardlow Enterprises $660 1 payment
  5. Alaska Medical Technologies, LLC $467 5 payments
  6. Zimmer Biomet Holdings, Inc. $376 4 payments
  7. Heron Therapeutics, Inc. $159 3 payments
  8. FX Shoulder USA, Inc $124 1 payment
  9. KCI USA, Inc $74 1 payment
  10. Ethicon US, LLC $69 2 payments
  11. Other $82 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,896 23 payments
  2. Food and Beverage $4,410 107 payments
  3. Education $2,586 4 payments
Products named General payments · program years 2019–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $3,462 41 payments
  2. AEQUALIS PERFORM $1,034 15 payments
  3. MAKO $961 9 payments
  4. AEQUALIS PERFORM REVERSED $320 12 payments
  5. Persona $224 2 payments
  6. ROSA $154 2 payments
  7. ECHO PRESS-FIT HIP SYSTEM $145 1 payment
  8. AEQUALIS FLEX REVIVE $118 1 payment
  9. Zynrelef $94 2 payments
  10. REUNION $82 1 payment
  11. Other $882 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

258

Median for Orthopedic Surgery: 203

Drug cost

$1,345

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 205 $666
Naproxen Generic 21 $322
Celecoxib Generic 13 $234
Gabapentin Generic 19 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$370,566

Of which drugs: $7,838

Medicare patients

657

Average age 73

Services billed

4,885

397 women, 260 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Diabetes 24%
Ischemic heart disease 24%
Chronic kidney disease 18%
Depression 18%
Osteoporosis 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 12 768 $5,183
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 174 2,113 $1,535

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record